Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized comparison of AMLCG vs PETHEMA treatment concepts in newly diagnosed acute promyelocytic leukemia
DRKS00004313Phase 3Completed
- Sponsor
- Universitätsmedizin Mannheim
- Start
- Aug 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tretinoin, idarubicin, daunorubicin, cytarabine, mitoxantrone and 4 more in Acute promyelocytic leukaemia (APL) (2 arms), sponsored by Universitätsmedizin Mannheim. Started Aug 2012; status: completed.
02
Drugs
tretinoinidarubicindaunorubicincytarabinemitoxantrone
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on DRKS00004313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00004313.